Context: Several studies have evidenced the association between subclinical hyperthyroidism and cognitive impairment in the elderly. However, the effect of long-term TSH suppressive therapy on the cognitive function in elderly patients with differentiated thyroid carcinoma (DTC) is still unclear.
D
ifferentiated thyroid carcinoma (DTC) is the most frequent endocrine cancer, and its incidence has increased by greater than 4% every decade for the last 30 years (1) . In patients with DTC, TSH-suppressive therapy using exogenous levothyroxine after initial surgical treatment is recommended because it inhibits further growth of the residual neoplastic tissue (1, 2) . However, there is growing interest in the potential harmful effects brought on by the long-term TSH-suppressive therapy because of the high survival rate after the initial treatment of DTC (1) . In particular, increased cardiovascular and fracture risk by exogenous subclinical thyrotoxicosis have been reported (1, (3) (4) (5) (6) . Therefore, not only the potential benefit but also the potential risk of TSH suppression should be considered, especially in elderly patients.
Thyroid hormone, an important neuroregulator during the development of the central nervous system (CNS), has been thought to have an important role in neurocognitive function after the CNS development (7) . Thyroid dysfunction in adults has been reported to be associated with mood change, memory impairment, behavioral abnormalities, irritability, and psychosis (7) . In addition to overt hypo-or hyperthyroidism, the relationship between subclinical hyperthyroidism and cognitive impairment has also been validated in several studies, especially in old-age subjects (8 -12) . In this regard, the clinical impact of TSHsuppressive therapy, iatrogenic subclinical thyrotoxicosis by exogenous levothyroxine, on the cognitive function of elderly DTC patients should be verified.
A single study recently reported the impaired cognitive function in DTC patients treated with TSH-suppressive therapy compared with control subjects (13) . The results were explained by the toxic effect of excessive thyroid hormone on the CNS. However, various mechanistic possibilities explaining the association between subclinical hyperthyroidism and cognitive impairment were suggested, one of which was reduced TRH, which in turn reduces TSH in the brain with neurodegenerative change (9) . This explanation was supported by our previous data, which demonstrated that lower serum TSH concentration within a reference range was associated with the future development of mild cognitive impairment and dementia in elderly subjects (14) . If we accept the explanation of reduced TRH/TSH in cognitive impairment to be plausible, then TSH suppression by exogenous levothyroxine in DTC patient might not be harmful to their cognitive function. Moreover, the previous study that reported the harmful effects of TSH suppression on the cognitive function had a relatively small number of study participants, and the control subjects of that study were not matched for variables such as depressive mood, which is an important risk factor of cognitive impairment (13) .
In the present study, we included 50 elderly DTC patients aged 65 years or older and have maintained TSHsuppressive therapy for more than 5 years after thyroidectomy. Their comprehensive cognitive function domains including memory, language, and visuospatial and executive function were compared with those of age-, sex-, education period-, and depressive mood-matched control subjects using various neuropsychiatric tests. If TSH suppressive therapy using exogenous levothyroxine affected the cognitive function of elderly DTC patients, different results in one or more neuropsychiatric tests would be demonstrated between patients and control subjects.
Materials and Methods

Sample size measurement and objectives
We referred to a previous study that investigated the differences in the cognitive function of DTC patients and normal control subjects (13) for the sample size measurement. Trail Making Test A and B were used in both the previous and present studies, and these tests showed some differences between the patient and control groups in the previous study (Trail Making Test A, patients vs controls, 34.1 Ϯ 9.5 vs 28.3 Ϯ 11.8, P ϭ .002; Trail Making Test B, 76.98 Ϯ 21.3 vs 62.1 Ϯ 21.7, P ϭ .010) (13) . According to these results, 41 patients and 82 control subjects are needed to determine the difference in Trail Making Test A between 2 groups (80% power, two sided type I error of 5%). For Trail Making Test B, 25 patients and 50 control subjects are needed. Therefore, our primary objective is to compare Trail Making Test A and B results between the patient and control groups. The secondary objective is to compare the comprehensive cognitive function domains between the 2 groups. We will also evaluate the correlation between cognitive function and other parameters associated with TSH-suppressive therapy.
Subjects
A total of 99 patients aged 65 years or older who were diagnosed with DTC or started in follow-up of DTC in Seoul National University Bundang Hospital (SNUBH) from October 2003 to May 2008 were eligible. They have maintained TSHsuppressive therapy with levothyroxine for longer than 5 years after thyroidectomy with or without radioactive iodine ( 131 I) therapy. Among them, 13 patients were out of touch and 36 patients refused to participate. The remaining 50 patients (mean age 70.9 Ϯ 5.0 y; male to female ratio 8:42) who agreed to participate were included in this study. We also recruited control subjects of twice as many as the number of patients who were matched for age, sex, education period, and depressive mood. These control subjects were recruited from the community-based cohort of randomly sampled elderly aged 65 years or older in Seongnam City, Korea, where SNUBH is located (15) .
Depressive mood was assessed using the Korean version of the Geriatric Depression Scale (GDS-K) (16) and matched by the GDS-K scores between patient and control groups. A total of 90 control subjects were finally included in this study because one case did not match the depressive mood and another nine cases were excluded due to abnormal thyroid function. At least one control subject was matched to each DTC patient. In the patient group, the mean duration of DTC was 8.6 Ϯ 3.7 years (range 5.3-23.6 y). All patients were on a stable dose of levothyroxine (mean 109.5 Ϯ 24.8 g/d; range 50 -175 g/d) and had no evidence of residual DTC. All subjects included in the patient and control groups had no chronic hepatitis and no neuropsychiatric disorders including drug or alcohol addiction, stroke, and Parkinsonism. Thirty-one subjects in the patient group had hypertension or hypertension and type 2 diabetes mellitus (T2DM) (hypertension, n ϭ 21; both hypertension and T2DM, n ϭ 10). In the control group, 58 subjects had hypertension and/or T2DM (hypertension, n ϭ 44; T2DM, n ϭ 3; both hypertension and T2DM, n ϭ 11). All subjects with T2DM or hypertension maintained well-controlled serum glucose levels and blood pressure with a stable dose of medication. The general health status of older adults were also assessed using the Cumulative Illness Rating Scale (CIRS) (17, 18) . This study was approved by the Institutional Review Board of the SNUBH. Subjects were fully informed regarding the study participation, and written informed consents were provided to the subjects or to their legal guardians.
Treatment and follow-up
All patients with DTC underwent treatment according to our local guidelines as previously published (19) . Korean Thyroid Association (KTA) guidelines for the long-term management of DTC (19) recommended a similar degree of TSH suppression with the American Thyroid Association guidelines (2) according to the risk-group stratification. According to the KTA guidelines for long-term management of DTC, serum TSH levels below 0.1 mIU/L are recommended in patients with persistent disease; serum TSH levels of 0.1-0.5 mIU/L are recommended in patients free of disease but who presented with high-risk disease; and a lower normal range (0.3-2.0 mIU/L) of serum TSH is recommended, even in patients at low risk for recurrence (19) . All 50 DTC patients included in this study had no evidence of persistent disease, and low-risk diseases and intermediate-risk diseases were present in 10 and 40 patients at the time of diagnosis of DTC, respectively. The average serum TSH level during the last 5 years was 0.18 (0.16) mIU/L in the 10 patients with low-risk diseases and 0.16 (0.23) mIU/L in the 40 patients with intermediate-risk diseases. In five of the patients with low-risk disease, the average serum TSH levels were lower than the KTA guidelines (0.3-2.0 mIU/L in low risk disease). In all patients, 5-year average serum TSH levels were not higher than those recommended by the KTA guidelines.
Assessment of cognitive function
To properly diagnose cognitive impairment, neuropsychological tests that can cover memory, language, and visuospatial and executive function should be administered. The Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery (20) is one of the most popular neuropsychological battery for evaluating dementia patients and elderly with cognitive disorders. We used the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Assessment Battery (CERAD-K-N) (20) Well-established normative data of target populations for each cognitive test are crucial in diagnosing cognitive impairment. All tests that have been used in the current study had a well-powered normative data of elderly Koreans. All neuropsychological tests were administered by three neuropsychiatrists who completed their fellowship training program for geriatric psychiatry provided at SNUBH and are experts in dementia research.
Hormonal measurements
Concentrations of serum free T 4 and TSH were measured by immunoradiometric assays ( DiaSorin S.p.A.; TSH: CIS BioInternational). The reference range of free T 4 and TSH was 0.7-1.8 ng/dL and 0.4 -4.1 mIU/L, respectively.
Data analysis
Values with normal distribution were expressed as mean Ϯ SD, and values with nonnormal distribution were expressed as median (interquartile range). A generalized estimating equation (GEE) analysis was used for the comparison of parameters between the patient and control groups. A Pearson correlation coefficient was used to estimate the relationships between cognitive domains and other parameters. A linear regression analysis was used to estimate the multiple correlations between cognitive function and other factors. All statistical analyses were performed with STATA software (version 13; StataCorp LP). Data with a value of P Ͻ .05 were considered significant and Bonferroni correction was used in multiple statistical tests.
Results
Subject characteristics in patient and control groups
The characteristics of the subjects are shown in Table 1 , which shows that age, sex, education period, and GDS-K score were not different between the patient and control groups. In the patient group, the mean dose of levothyroxine at the time of the evaluation of cognitive function was 109.5 Ϯ 24.8 g/d, and the mean dose of levothyroxine during the last 5 years was 129.2 Ϯ 24.0 g/d. Serum TSH levels at the time of evaluation of cognitive function and average serum TSH levels during the last 5 years were lower in patient group compared with those of the control group. On the contrary, the serum free T 4 levels at the point of evaluation, and the average serum T 4 levels during the last 5 years were higher in the patient group compared with those of the control group. One the other hand, the CIRS and the prevalence of hypertension and T2DM were similar between the 2 groups.
Comparison of cognitive function domains between patients and control groups
No differences in the scores of each neuropsychological test were found between the patient and control groups after Bonferroni correction for the number of neuropsychiatric tests(data with a value of P Ͻ .004 were considered significant; Table 2 ).
Correlation between cognitive function and other parameters
The interaction term was fitted in the linear regression model to test whether the association between other parameters and cognitive function was modified, depending on the study group; MMSE, Trail Making Test A, Trail Making Test B, and Wordlist Memory test showed statistically different association with free T4 levels at the time of cognitive evaluation according to the study group. Therefore, we performed further correlation analyses stratified by the study group. Our analysis of the correlations between the cognitive functions and other parameters associated with TSH-suppressive therapy in the patient group showed that none of the cognitive domains were correlated with the duration of DTC or the dose of levothyroxine. Additionally, the average serum free T4 and TSH levels during the last 5 years were not associated with any of the cognitive domains (data not shown). However, patients with higher serum free T4 level at the time of cognitive evaluation performed better on two cognitive function tests: MMSI and Trail Making Test A, even after Bonferroni correction for the number of neuropsychiatric tests (Table 3) . On the contrary, in the control group, all parameters including the serum free T 4 levels were not associated with any of the assessed cognitive domains (data not shown). The different distributions of the scores of MMSE and Trail Making Test A between patient and control groups are presented in Figure 1 .
Independent association between free T 4 levels and cognitive function in the patient group
We performed a linear regression analysis to investigate the independent association between free T 4 levels at the cognitive evaluation and the scores of MMSE and Trail Making Test A after adjustment for other factors affecting cognitive function. The association of free T 4 levels with Trail Making Test A was maintained after adjusting for age, education period, GDS-K, and CIRS, even when we set the threshold of the P value to .004 (threshold of P value applied in correlation analyses) ( Table 4) .
Discussion
To our knowledge, this is the first study demonstrating the clinical safety of long-term TSH suppressive therapy on the cognitive function of elderly DTC patients. In this study, all assessed cognitive domains were comparable in patient and control groups. Although the forward Digit Span Test showed a difference between 2 groups without Bonferroni correction for multiple tests (P ϭ .044), the scores of 5.5 (patient group) and 6.0 (control group) in this test are all decided as a normal function, even in the younger population. Therefore, this statistical difference in the Digit Span Test between the patient and control groups does not present any clinical meaning. Our results show that the cognitive function of elderly DTC patients under a long-term TSH suppressive therapy was not impaired compared with control subjects. On the other hand, our previous prospective cohort study reported that lowbut-normal serum TSH level could be a predictive factor for the future risk of cognitive decline, including mild cognitive impairment and dementia in the euthyroid elderly (14) . In addition, other previous prospective studies suggested that subclinical hyperthyroidism or low serum TSH level was associated with the risk of dementia in the elderly (10 -12) . The results of the present study are not contradictory to those previous reports but rather present some important clues to explain the previously reported association. A recent review suggested several possible mechanisms underlying the association of low TSH level with the risk of cognitive decline (9) .
Of the two widely accepted explanations, the first and the conventional explanation is the toxic effect of excessive thyroid hormone on the CNS (9). Brain oxidative stress caused by an excess of thyroid hormone or thromboembolism from the cardiac effects of mild hyperthyroidism have been suggested as underlying mechanisms (9, 14, 23) . Second, neurodegenerative changes in the brain, which may cause a cognitive decline, can also result in a reduced secretion of TRH in the brain and, in turn, reduce the secretion of TSH (9) . TRH is secreted not only from the hypothalamus but also from other areas of the brain and is known to play a role as a CNS neurotransmitter, suggesting that TRH secretion may decrease in the brain of the subjects with cognitive impairment (9, 24) . According to our data, long-term iatrogenic subclinical thyrotoxicosis or a mild excess of thyroid hormone did not result in a cognitive decline in elderly subjects. This result suggests that the association between low serum TSH level and cognitive decline in the elderly is not due to the toxic effect of thyroid hormone excess. Also in our previous study, we showed that elderly subjects with lower TSH levels, not higher levels of free T 4 , were at a higher risk of future cognitive decline and suggested the theory of reduced TRH in the degenerated brain as the most reliable explanation (14) .
In our data, two neuropsychological tests including the MMSE, a test for global cognitive function, and the Trail Making Test A, a test for cognitive processing speed, were correlated with serum free T 4 levels in the patient group, and the Trail Making Test A showed independent association with serum free T 4 levels after adjusting other factors affecting cognitive function. This correlation demonstrated better cognitive performance in DTC patients with higher serum free T 4 levels, whereas the cognitive function was not related with serum free T 4 or TSH levels in control subjects. This discrepant result between the patient and control groups suggests that the relationship between serum thyroid hormone levels and the cognitive function can vary according to the source of thyroid hormone or the condition of hypothalamic-pituitary-thyroid axis. Also in previous studies, the potential benefit of the thyroid hormone treatment on the cognitive function was suggested in several animal studies (25) (26) (27) , whereas endogenous subclinical hyperthyroidism was associated with dementia or poorer performance on the MMSE in elderly subjects (9, 28 -33) . On the basis of our results, it can be postulated that mildly excessive thyroid hormone resulting from exogenous levothyroxine may improve some cognitive domains in the condition of deficient endogenous thyroid hormone or impaired hypothalamic-pituitary-thyroid axis.
This study includes some important clinical implications. Increased cardiovascular risk and fracture risk by exogenous subclinical thyrotoxicosis have already been reported (1, (3) (4) (5) (6) , and there are growing concerns regarding the potential harmful effect of long-term TSH suppressive therapy, especially in elderly patients. In this regard, our data presenting TSH suppression to be safe for the cognitive function of elderly DTC patient are noteworthy. Our data also suggest that a mild excess of thyroid hormone resulting from exogenous levothyroxine may provide beneficial effects on some cognitive domains in conditions in which patients may lack endogenous thyroid hormone, such as severe overt hypothyroidism or the thyroidectomized state. In addition, the possibility of the novel therapeutic application of thyroid hormone for dementia can be postulated. However, further large studies with a prospective design are needed to confirm the possible causal effects of exogenous levothyroxine on the cognitive function in this population because this study is a cross-sectional, case-control study, and our results of the correlation between free T 4 and cognitive function was from a small study population. The potential limitations of the present study include small sample size. Although 50 patients and 90 control subjects may be sufficient to investigate the difference between DTC patients and control subjects for at least Trail Making Tests, there still is a possibility that the sample size of our study is inadequate to investigate the differences of other neuropsychometric measurements. In addition, the sample size can be insufficient to demonstrate the equivalence of cognitive function between two groups because the estimated sample size of this study was based on the hypothesis that the results of Trail Making Tests are different between DTC patients and control subjects. A large study is needed to continue to confirm the safety of TSHsuppressive therapy on cognitive function. Nonetheless, the confidence intervals on the difference from GEE analyses did not include large, clinically meaningful differences in all neuropsychiatric tests, and it is noticeable that our study included the largest sample size among the studies investigating the effect of iatrogenic subclinical thyrotoxicosis on the cognitive function in elderly subjects. On another note, although some patients who were diagnosed with T2DM and/or hypertension had well-controlled serum glucose and blood pressure with a stable dose of medication, these comorbid medical conditions could still affect the cognitive function in DTC patients. However, the ratio of subjects with T2DM or HTN was not significantly different between the patient and control groups, and CIRS, a reliable scoring system for estimating comorbidity (17, 18) , was not different between the 2 groups. In addition, a selection bias cannot be excluded. Although control subjects were randomly sampled, all DTC patients included in this study maintained regular follow-up for their disease in our institution and agreed to participate in this study. Therefore, there is a possibility that patients who were relatively more interested in their physical and mental health were included in this study. To minimize this bias, we intensively matched for other factors affecting the cognitive function. Finally, the present study was performed in a single medical center and the male to female ratio of the patient group was 8:42. Thus, our results cannot be applied to the general population, and an external validation should be performed.
In conclusion, we observed no differences in the cognitive function between elderly DTC patients who received a long-term TSH suppressive therapy and euthyroid control subjects. To our knowledge, this is the first and largest study to demonstrate the long-term safety of TSHsuppressive therapy on the cognitive function of elderly DTC survivors. Furthermore, the positive correlations between serum free T 4 levels and some cognitive domains suggest the potential beneficial effects of exogenous levothyroxine on the cognitive functions of patients who lack endogenous thyroid hormone.
